Key Highlights

  • Up 104.40 per cent over one year and 46.07 per cent year to date, the strongest of the eight on both measures.
  • RSI at 66.22 with a Commodity Channel index of 139.56 and a Strong buy Moving Average rating.
  • Three and six month windows are negative, at -15.14 per cent and -4.41 per cent.

Technical position

RSI 14 reads 66.22, among the higher readings in the group though still below the conventional 70 threshold. The Commodity Channel Index sits at 139.56, well above the 100 line, with the stochastic at 78.57 on %K against 75.29 on %D. Momentum over ten periods reads 0.40 and the Awesome Oscillator 0.34, both mid-range for the group. The technical rating is Buy with a Strong buy moving average rating and a Neutral oscillator rating, and the 21-period exponential moving average holds above the 50-period average.

Fundamental snapshot

Cabaletta Bio sits in health technology with a Market Capitalisation of USD 551.02 million. The shares last traded at USD 3.25, up 0.93 per cent on the session. Trailing Diluted Earnings per Share is negative at USD 1.58, so no price to earnings ratio applies, with earnings per share growth of 41.56 per cent. No Dividend is paid. Analyst consensus reads Strong buy.

Price performance

The stock leads its peer group over one year at 104.40 per cent and is up 46.07 per cent year to date, 19.93 per cent over one month and 10.17 per cent over one week. The intervening windows are weaker, down 15.14 per cent over three months and 4.41 per cent over six months. On an all time basis the shares are down 63.89 per cent. One month Volatility reads 5.84 per cent.

This article is general information only and does not take into account any individual objectives, financial situation or needs. It is not a recommendation to buy, sell or hold any security. All details are as stated in the company announcement or third party research referenced and are subject to change. Past performance is not a reliable indicator of future performance. Investors should consider the appropriateness of any information having regard to their own circumstances and seek independent financial advice before making any financial decision.